@prefix np: . @prefix npx: . @prefix ns1: . @prefix orcid: . @prefix prov: . @prefix rdf: . @prefix rdfs: . @prefix sub: . @prefix this: . @prefix xsd: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { rdf:OBJECT rdfs:label "additional treatment" . rdf:OBJECT-POSITION rdfs:label "(19, 27)" . rdf:PREDICATE rdfs:label "received" . rdf:SUBJECT rdfs:label "patients" . rdf:SUBJECT-POSITION rdfs:label "(19, 27)" . ns1:receive ; rdfs:label "patients" . rdfs:label "treatment" . } sub:provenance { sub:_assertion prov:wasGeneratedBy "S&T TWOC Project - version 4" . sub:assertion prov:generatedAtTime "2023-06-12T10:38:41.226484"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0003-4692-1377 . rdf:Statement rdfs:label "34 out of 68 (50%) patients in the standard treatment group and 7 out of 90 (7.7%) in a cohort of patients who received additional treatment with tocilizumab once (either 400 mg intravenous or 324 mg subcutaneous) died." . rdfs:ABSTRACT-UID rdfs:label "6yhgtgzz" . rdfs:TRIPLE-UID rdfs:label "6yhgtgzz-TRIPLE-ABSTRACT-1" . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "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"; npx:hasSignature "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"; npx:hasSignatureTarget this: . this: prov:wasAttributedTo orcid:0000-0003-4692-1377 . }